• May 7, 2024

Corticosteroids are medications used as part of the treatment for respiratory problems , and musculoskeletal injuries or disorders due to its anti-inflammatory and immunosuppressive properties. However, there is a lot of misinformation about its use, as well as a high frequency of self-medication.

According to Dr. Eduardo Gabriel Desentis, otorhinolaryngologist at the National Medical Center Siglo XXI , corticosteroids, also known as corticosteroids or glucocorticoids, are a variety of hormones produced by the adrenal glands that repeat the chemical action of cortisone produced by the body, which influences the assimilation of proteins, carbohydrates in (carbohydrates) , lipids (fats) and minerals.
 

You may also be interested: Corticosteroids support the production of hormones

Myths and realities

One of the most frequent myths attributable to corticosteroid treatments in respiratory problems , As the asthma , is that corticosteroids are dangerous.

Actually, the National Institute of Health (NIH) of the United States suggests inhaled corticosteroids (ICS), as the preferred method for the treatment of chronic asthma , provided they are used under medical prescription, because they are much more effective in relieving nasal obstruction than antihistamines.

You may also be interested in: Most common allergies

Treatment of musculoskeletal problems

On the other hand, in the case of musculoskeletal problems, such as rheumatoid arthritis, lumbago or osteoarthrosis, to mention a few, the Dr. Jesús Solís González, orthopedist and traumatologist member of the Mexican College of Orthopedics , corticosteroids are part of the treatment because they effectively reduce localized inflammation and pain.

Also, according to the surgeon of the spine, hip, shoulder and knee, the use of corticosteroids is constituted with a primary and effective alternative, against the use of anti-inflammatories or anesthetics, for the treatment of this class of ailments.

Video Medicine: 13 MYTHS THAT IT'S SHAMEFUL TO BELIEVE IN (May 2024).